EsoBiotec
Pioneering the development of innovative cancer treatments through advanced cell engineering solutions.
Pioneering the development of innovative cancer treatments through advanced cell engineering solutions.
EsoBiotec:
EsoBiotec is a Belgian biotechnology business founded in 2020, pioneering the development of innovative cancer treatments through advanced cell engineering solutions. The company's slogan "Pioneering the development of innovative cancer treatments through advanced cell engineering solutions" reflects its core focus. EsoBiotec is dedicated to the discovery of novel cancer therapies with the objective of enabling the human body to fight cancer by delivering 'in vivo' cell engineering to patients.
The latest milestone for EsoBiotec is the €2.00M Series A investment received on 12 December 2023 from Invivo Capital Partners. This investment not only signifies confidence from the investors in the company's vision but also provides the necessary capital to further its research and development in the biotechnology sector.
Overall, with its clear focus on innovative cancer treatments and a recent significant Series A investment from Invivo Capital Partners, EsoBiotec is positioned to make impactful strides in the biotechnology industry.| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | €2.00M | 1 | Invivo Capital Partners | 12 Dec 2023 |
| Seed Round | €3.00M | 4 |
|
30 Sep 2021 |
No recent news or press coverage available for EsoBiotec.
We care about your data, and we'd love to use cookies make your experience better.